Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses

Salvato in:

Dettagli Bibliografici
Pubblicato in:	bioRxiv (Dec 12, 2024)
Autore principale:	Lei, Jonathan T
Altri autori:	Dobrolecki, Lacey E, Huang, Chen, Srinivasan, Ramakrishnan R, Vasaikar, Suhas V, Lewis, Alaina N, Sallas, Christina, Zhao, Na, Cao, Jin, Landua, John D, Chang In Moon, Liao, Yuxing, Hilsenbeck, Susan G, Osborne, C Kent, Rimawi, Mothaffar F, Ellis, Matthew J, Petrosyan, Varduhi, Wen, Bo, Li, Kai, Saltzman, Alexander B, Jain, Antrix, Malovannaya, Anna, Wulf, Gerburg M, Marangoni, Elisabetta, Li, Shunqiang, Kraushaar, Daniel C, Wang, Tao, Damodaran, Senthil, Zheng, Xiaofeng, Meric-Bernstam, Funda, Echeverria, Gloria V, Meenakshi Anurag, Chen, Xi, Welm, Bryan E, Welm, Alana L, Zhang, Bing, Lewis, Michael T
Pubblicazione:	Cold Spring Harbor Laboratory Press
Soggetti:	AstraZeneca AbbVie Inc Pfizer Inc Envigo Seattle Genetics Inc Antagonism Models Experimental research Cancer therapies Cytokeratin Biotechnology Oncology Disease management Breast cancer Transcriptomics Proteomics Royalties Histone deacetylase Stockholders Biomarkers Research funding Licenses Carboplatin Chemotherapy Patients Chemoresistance Fees & charges Xenografts
Accesso online:	Citation/Abstract Full Text - PDF Full text outside of ProQuest
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Lascia un commento!